Shots:

• Codexis to receive an upfront payment- reimbursement for research and development fees- development and commercial milestones along with royalties on sales of any commercial product developed under the collaboration
• The alliance will initially work on three programs to develop novel gene therapies for lysosomal storage disorders and blood factor deficiencies. Codexis will create the novel enzyme sequences for advancement as gene therapies into pre-clinical development utilizing its CodeEvolver protein engineering platform
• Takeda is responsible for the pre/ clinical development and commercialization of gene therapy products resulting from the collaboration programs. In addition to three initial programs- Takeda may extend it up to four additional programs for other indications

Click here­ to­ read full press release/ article | Ref: GlobeNewswire | Image: Owler